Drugs / Pylopass
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02051348 Comparator | Jan → Dec 2014 | Helicobacter pylori infectious disease | Atlantia Food Clinical Trials | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pylopass | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02051348 ↗ |
| Modality | Other / unclassified | “Pylopass contains the probiotic strain Lactobacillus reuteri” NCT02051348 ↗ |
| Route | Oral | “oral administration of Pylopass leads to a reduction in UBT values in volunteers with H. pylori” NCT02051348 ↗ |